You are here

Office of Innovation Management

The Office of Innovation Management (OIM) is UL Lafayette’s academic technology transfer unit. Academic technology transfer is the process of developing and commercializing new academic discoveries for the benefit of society. Often, the efficient management of intellectual property (IP) is a critically important first step in the academic technology transfer process. Prudent IP management permits the OIM to identify and establish strategic industry-academia partnerships for development of University IP, and pursue license and/or sponsored-research negotiations and other commercial arrangements with external parties.

The OIM provides a spectrum of technology transfer & IP services. We stimulate & triage incoming ideas; conduct commercial & IP surveys; and employ strategic IP management mechanisms inducing patent, trademark and copyright protection to maximize commercial & societal benefit. If you have any questions, give us a call at 337-735-5483 or send us an email at


COVID-19 Technology Access Framework

We strongly believe that while intellectual property rights can often serve to incentivize the creation of new products, such rights should not become a barrier to addressing widespread, urgent and essential health-related needs. To address the global COVID-19 pandemic, we are each implementing technology transfer strategies to allow for and incentivize rapid utilization of our available technologies that may be useful for preventing, diagnosing and treating COVID-19 infection during the pandemic. To achieve our common goal, we each individually commit to the following guidelines:

1.   We are committed to implementing COVID-19 patenting and licensing strategies that are consistent with our goal of facilitating rapid global access. For most types of technologies, this includes the use of rapidly executable non-exclusive royalty-free licenses to intellectual property rights that we have the right to license, for the purpose of making and distributing products to prevent, diagnose and treat COVID-19 infection during the pandemic and for a short period thereafter.  In return for these royalty-free licenses, we are asking the licensees for a commitment to distribute the resulting products as widely as possible and at a low cost that allows broad accessibility during the term of the license.

2.   We are committed to making vigorous efforts to achieve alignment among all stakeholders in our intellectual property, including research sponsors, to facilitate broad and rapid access to technologies that have been requested to address the COVID-19 pandemic.

3.  We are committed to making any technology transfer transactions related to addressing the COVID-19 pandemic our first priority, and to minimizing any associated administrative burdens.

The initial signatories include:

Stanford University

Harvard University

Massachusetts Institute of Technology

For further information, please contact the UL Lafayette OIM at or 337-849-9410.